WO2014189335A1 - Protéine de fusion comprenant une protéine de liaison à l'annexine a1, protéine p53 et protéine p18 ou p16, et composition pour la prévention ou le traitement du cancer, la comprenant - Google Patents

Protéine de fusion comprenant une protéine de liaison à l'annexine a1, protéine p53 et protéine p18 ou p16, et composition pour la prévention ou le traitement du cancer, la comprenant Download PDF

Info

Publication number
WO2014189335A1
WO2014189335A1 PCT/KR2014/004644 KR2014004644W WO2014189335A1 WO 2014189335 A1 WO2014189335 A1 WO 2014189335A1 KR 2014004644 W KR2014004644 W KR 2014004644W WO 2014189335 A1 WO2014189335 A1 WO 2014189335A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
cancer
fusion protein
domain
annexin
Prior art date
Application number
PCT/KR2014/004644
Other languages
English (en)
Korean (ko)
Inventor
이정민
이정훈
김정민
강혜윤
이재일
Original Assignee
삼성전자 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 삼성전자 주식회사 filed Critical 삼성전자 주식회사
Publication of WO2014189335A1 publication Critical patent/WO2014189335A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4728—Calcium binding proteins, e.g. calmodulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Definitions

  • Fusion protein comprising annexin A1 binding protein, p53 protein, and pl8 or pl6 protein and composition for preventing or treating cancer comprising the same
  • the present invention relates to an anneal A1 binding protein, a p53 protein, and a fusion protein to which a pl8 or pl6 protein is bound, preparation of the fusion protein, and a pharmaceutical composition for preventing or treating cancer comprising the fusion protein.
  • CDK cyclin-dependent kinase
  • Cyclin-CD complex phosphorylates proteins involved in cell proliferation, resulting in cell division. Induce. Proteins that induce DNA replicators are mainly Cyclin D / E and CDK 4/6, and CDK 4/6 phosphorylates Rb (Retinoblastoma) protein to transcription of transcription factor E2F. Make it active. The proteins that induce cell division are mainly Cyclin A / B and CDK 2/1, and their Cyclin-CDK complex is called MPF (M-phase promoting factor).
  • MPF M-phase promoting factor
  • p21 protein that act as all been 'DNA damage checkpoint in G1.
  • the p21 gene is expressed by p53, a tumor suppressor gene that is activated when DNA is damaged.
  • p21 binds to the Cyclin-CDK complex that induces a DNA replicator and inhibits the kinase activity of CDK4 / 6/2, thereby preventing phosphorylation of the Rb protein.
  • the cells stay in G1 phase and have time to repair damaged DNA. If the DNA damage is severely unacceptable to cells, p53 expresses the gene of Bax protein, an apoptosis-inducing gene.
  • the action of p53 in the regulation of cell proliferation is to express p21 gene to temporarily stop cell proliferation, or p53 protein combined with ASPP protein, which is a p53-binding protein, expresses Bax gene. It can be divided into two things: apoptosis inducing. Apoptosis, also known as programmed cell death, is when cell death is beneficial at the individual level, such as when cells are no longer needed in the tissue, when they have been invaded by a virus or when they have been converted into cancer cells. It is a mechanism to commit suicide by itself.
  • CDK inhibitors that regulate cell cycle can be classified into two groups, CIP CDK inhibitor protein family and INK4 (Inhibitors of cyclin-dependent kinase 4).
  • CIP has p21 and p27.
  • INK4 mainly inhibits the activity of CDK 4, 6, and there are pl5, pl6, pl8 and pl9.
  • a balance between the tumor suppressor gene and the proto-oncogene In order to regulate cell proliferation, a balance between the tumor suppressor gene and the proto-oncogene must be maintained. Mutation of the gene of the p53 protein, a tumor suppressor gene, leads to abnormal cell proliferation because it cannot induce apoptosis of abnormal cells. Also Precancerous genes, which are normal cell proliferation factors, are mutated (such as viral gene replacement) or overexpressed to become cancer genes, leading to abnormal cell proliferation such as cancer cells.
  • the oncogene causes growth of cells with abnormal activity, intracellular signaling proteins, and thus causes false signal transduction, so that cell proliferation occurs even without external proliferation signals.
  • One embodiment provides a fusion protein comprising an annexin A1 binding protein, a .p53 protein or fragment thereof, and a pl8 or pl6 protein.
  • Another embodiment provides a polynucleotide encoding the fusion protein.
  • Another embodiment provides a recombinant vector comprising the polynucleotide.
  • Another embodiment provides a cell transformed with the recombinant vector.
  • Another embodiment provides a method of preparing a fusion protein comprising culturing the transformed cells.
  • Another embodiment provides a pharmaceutical composition for preventing and / or treating cancer comprising the fusion protein as an active ingredient.
  • Another embodiment provides a method of treating cancer comprising administering to a subject a therapeutically effective amount of said fusion protein.
  • FIG. 1 schematically shows an example of a fusion protein according to one embodiment.
  • 2 is a result showing that the fusion protein (protein complex # 1) binds to annexin A1 according to one embodiment, (1) is a result in the absence of calcium ions, (2) is a calcium ion The results are shown under these existing conditions.
  • Figure 3 shows the results confirming the cell growth inhibition effect according to the treatment concentration of the fusion protein (protein complex # 1) in HCC1806 cell line.
  • Figure 4 shows the results confirming the cell growth inhibition effect according to the treatment concentration of the fusion protein (protein complex # 1) in HCC116 cell line. [Best form for implementation of the invention]
  • a fusion protein comprising annexin A1 binding protein, p53 protein or fragment thereof, and pl8 or pl6 protein.
  • the fusion protein may be an in vitro stabilization protein, a membrane transfer sequence (MTS) domain, a nuclear-cytoplasm signal domain, and an in vivo stabilization protein. It may further comprise one or more selected from the group consisting of.
  • Another example provides a polynucleotide encoding the fusion protein.
  • Another example provides a recombinant vector comprising the polynucleotide.
  • Another example provides a cell transformed with the recombinant vector.
  • Another example provides a method for producing a fusion protein comprising culturing the transformed cells.
  • compositions for preventing and / or treating cancer comprising the fusion protein as an active ingredient.
  • the pharmaceutical composition may further comprise a pharmaceutically acceptable carrier, diluent and / or excipient in an amount normally used as necessary.
  • CDK (Cyclin-dependent kinase) protein plays a major role in cancer development, and as an inhibitor thereof CIP (CDK inhibitor) protein lineage protein and INK4 (inhibitors of cyclin—dependent kinase 4) lineage proteins.
  • the fusion protein according to one embodiment of the present invention is a p53 protein that regulates CIP strain protein expression and pl8 or pl6 protein belonging to the INK4 strain protein, and simultaneously exerts CIP strain protein activity and INK4 protein activity to improve cancer. Prophylactic and / or therapeutic effects may be obtained.
  • the p53 protein may be a polypeptide or fragment thereof having an amino acid sequence provided by NCBI accession number NPJD00537.
  • P53 protein is used herein to mean both full-length protein and fragments thereof unless otherwise stated.
  • the p53 protein may be a transcriptional activation domain of p53 protein having the amino acid sequence of SEQ ID NO: KGlu Thr Phe Ser Asp Leu Trp Lys Leu Leu Pro Glu Asn).
  • the p53 protein fragment having the amino acid sequence of SEQ ID NO: 1 means a transcriptional active domain comprising the 18th to 26th amino acid sequence of the human p53 protein, which is a site that binds to Mdm2 in the p53 protein.
  • the transcriptional activation domain of p53 significantly increases the stability of p53 in vivo by binding to Mdm2, which is responsible for p53 degradation, and expresses p21 gene encoding CDK inhibitor protein by p53 to temporarily stop cell proliferation.
  • p53 combined with the apoptosis-stimulating protein of p53 (ASPP), a p53-binding protein, expresses the Bax gene and causes cell death.
  • tumor suppressor pl8 or pl6 protein plays a role in inhibiting the activity of CDK 4, 6. Therefore, the fusion protein in which the transcriptional activation domain of p53 and the pl8 or pl6 protein are combined and the pharmaceutical composition containing the same as an active ingredient can be used as a novel anticancer agent.
  • the pl8 protein may be a polypeptide having an amino acid sequence of SEQ ID NO: 2.
  • the pl8 protein may be used by modifying (substituting, deleting, adding, deleting, etc.) some amino acid residues for the purpose of improving solubility, so long as it does not affect the overall protein activity.
  • the pl6 protein may be a polypeptide having an amino acid sequence of SEQ ID NO: 3.
  • the pl6 protein may be used by modifying (substituting, deleting, adding, deleting, etc.) some amino acid residues so long as it does not affect the overall protein activity for the purpose of improving solubility.
  • sequence of linking the p53 protein and pl8 or pl6 protein in the fusion protein is not limited, and includes both N-terminal -p53 protein -pl8 or pl6 protein -C terminus or N-terminal -pl8 or pl6 protein -p53 protein_C terminus forms.
  • p53 protein fragments and pl8 protein binding fusion protein may be one having the amino acid sequence of SEQ ID NO: 4, p53 protein fragments and pl6 protein binding fusion protein having an amino acid sequence of SEQ ID NO: 5 It may be.
  • the fusion protein of the present invention includes the Annexin A1 binding protein (Annexin A1BP) ol.
  • Annexin A1 binding protein binds to Annexin A1, which is specifically expressed in cancer cells, thereby enabling cancer cell targeting so that the fusion protein can selectively act only on cancer cells.
  • Annexin A1 binding protein may be exemplified by a peptide having an amino acid sequence selected from SEQ ID NO: 6 to SEQ ID NO: 14, but the scope of the present invention is not limited thereto, as long as it can achieve cancer cell targeting activity Fragments, peptides, analogs or variants of the A1 binding protein may be used.
  • the annexin A1 binding protein in the fusion protein may be located at the N-terminus or C-terminus of the p53 and pl8 or pl6 fusions.
  • the fusion protein of the present invention may include an annexin A1 binding protein p53 protein, and a pl8 or ⁇ protein in the order of ⁇ -terminal to C-terminal; A fusion protein comprising an annexin A1 binding protein, ⁇ 18 or ⁇ 16 protein, and ⁇ 53 protein in the N-terminal order of the C-terminus; a fusion protein comprising a ⁇ 53 protein, a ⁇ 18 or ⁇ 16 protein, and an annexin A1 binding protein in the order of ⁇ -terminal to C-terminal; a fusion protein comprising a ⁇ 18 or ⁇ 16 protein, a ⁇ 53 protein and an annexin A1 binding protein in the order of ⁇ -terminal to C-terminal It may be.
  • At least one member selected from the group consisting of in vitro stabilization protein, membrane transfer sequence (MTS) domain, nucleus-cytoplasm signal domain, and in vivo stabilization protein May include additional additions.
  • the position of the added polypeptide in the fusion protein is not limited, and the one or more polypeptides to be added may be included independently of the N-terminal, C-terminal, or p53 protein and pl8 or pl6 protein of the fusion protein. have.
  • the fusion protein is stabilized in vitro in the N-terminal direction of the p53 protein in the fusion protein comprising an annexin A1 binding protein, p53 protein, and pl8 or pl6 protein in the N-terminal to C-terminal order Protein, membrane transmembrane sequence domain and nuclear-cytoplasmic signal domain, further comprising at least one selected from the group consisting of membrane permeable sequence domain, nuclear-cytoplasmic signal domain, and in vivo in the C-terminal direction of pl8 or pl6 protein. It may further comprise one or more selected from the group consisting of stabilizing proteins.
  • the fusion protein may include an annexin A1 binding protein, a pl8 or pl6 protein, and a p53 protein in the order of N-terminus to C-terminus, in the ⁇ —terminal direction of the pl8 or ⁇ 16 protein. It further comprises one or more selected from the group consisting of an in vitro stabilizing protein, a membrane permeation sequence domain and a nuclear-cytoplasmic signal domain, or a membrane permeation sequence domain, a nuclear-cytoplasmic signal domain and a biomarker in the C—terminal direction of the ⁇ 53 protein. It may further comprise one or more selected from the group consisting of a stabilizing protein.
  • the fusion protein may comprise a ⁇ 53 protein, a ⁇ 18 or ⁇ 16 protein, and an annexin A1 binding protein, in the order of ⁇ -terminal to C-terminal, in the ⁇ -terminal direction of the annexin A1 binding protein. Further comprises at least one member selected from the group consisting of an in vitro stabilizing protein, a membrane permeation sequence domain and a nuclear-cytoplasmic signal domain, or is Annexin A1.
  • the c-terminal direction of the binding protein may further include one or more selected from the group consisting of a membrane permeation sequence domain, a nuclear-cytoplasmic signal domain, and an in vivo stabilizing protein.
  • the fusion protein may comprise a pl8 or pl6 protein, a p53 protein, and an annexin A1 binding protein in the order of N-terminus to C-terminus.
  • Direction further comprises at least one member selected from the group consisting of an in vitro stabilizing protein, a membrane permeation sequence domain and a nuclear-cytoplasmic signal domain, or a membrane permeation sequence domain, a nuclear- in the C-terminal direction of an annexin A1 binding protein. It may further comprise one or more selected from the group consisting of a cytoplasmic signal domain and an in vivo stabilizing protein.
  • the term “in vitro stabilization protein” refers to a protein for enhancing the solubility and stability of the fusion protein outside of the fusion protein, that is, when the fusion protein is experimentally purified. Means.
  • the ex vivo stabilizing protein is part of the fusion protein and should not induce immunogenicity in vivo.
  • the ex vivo stabilizing protein when introduced into the fusion protein, it is preferably located in the N-terminal direction of the fusion protein, but is not limited thereto.
  • the ex vivo stabilizing protein may additionally be located between pl8 and p53 in addition to both ends of the fusion protein.
  • the in vitro stabilizing protein may be, but is not limited to, ubiquitin or ubiquitin-like protein.
  • Ubiquitin (Ub) is the most conserved protein found in nature and consists of 76 amino acid sequences and is a water soluble protein that shows perfect homology between evolutionarily diverse species such as insects, trout and humans. Ubiquitin is also known as a protein that is stable to changes in pH, is not easily denatured even at high temperatures, and is stable to proteases. Thus, ubiquitin can improve the insolubility of the fusion protein.
  • the ubiquitin or ubiquitin-like protein is wild type ubiquitin, wild type ubiquitin-like protein, mutant ubiquitin And mutant ubiquitin-like protein may be selected from the group consisting of.
  • the mutant ubiquitin means that the amino acid sequence of the wild type ubiquitin is changed to another amino acid sequence, for example, ubiquitin in which Lys of wild type ubiquitin (SEQ ID NO: 15) is replaced with Arg, and / or wild type ubiquitin C ⁇ terminal RGG is RGA.
  • Ubiquitin ie, Gly present at 76th of the ubiquitin wild-type polypeptide is substituted with Ala).
  • the substitution is at least one selected from Lys present in 6, 11, 27, 29, 33, 48 and 63 of the wild type ubiquitin. And substitutions may be made independently or in combination at the positions of Lys.
  • the ubiquitin-like protein is a protein having similar characteristics to ubiquitin, for example, Nedd8, SUMO-1, SUMO-2, NUB1, PIC1, UBL3, UBL5 and ISG15 selected from the group consisting of It may be more than one, but is not limited thereto.
  • the ubiquitin or ubiquitin-like protein is
  • the C-terminus may comprise an amino acid sequence cleavable by the protease or an amino acid sequence not cleaved by the protease.
  • Amino acid sequences cleavable by the protease can be identified through a search database known in the art. For example, a protease and a cleavable amino acid sequence thereof can be used which is searched for at http://www.expasy.org/tools/peptidecutter/peptidecutter—enzymes.html.
  • the fusion protein is permeated into the cell, and then the ubiquitin or ubiquitin-like protein is cleaved by a protease in the cell, and includes annexin A1 binding protein, p53 protein, and pl8 or pl6 protein.
  • the fusion protein is able to function in the cell.
  • the fusion protein may contain membrane transmembrane sequence domains and / or nuclear-cytoplasmic signal domains, but since these polypeptides are very short in length, they do not affect the function of the fusion protein.
  • ubiquitin or ubiquitin-like proteins are not cleaved, ubiquitin or ubiquitin-like proteins are safe in vivo because they are not immunogenic, and because they do not fold because they do not contain cysteine, they do not cause fusion protein structural changes and the fusion proteins do not change in cells. It does not affect the function.
  • membrane transfer refers to the ability to transport a fusion protein to be delivered intracellularly and / or in vivo in vitro and / or in vivo.
  • membrane transfer sequence (MTS) domain means a polylapide having an amino acid sequence that can itself pass through the cell membrane of a phospholipid bilayer.
  • the membrane permeable sequence domain has a single hydrophobic region at its N-terminus, forms a helix structure, exhibits flexibility, and has a relatively short length of amino acids (7 to 17 amino acids). Characterized in having a.
  • the physical properties of the membrane permeable sequence domains usually exhibit hydrophobicity.
  • the membrane permeable sequence domain may be any polypeptide having an amino acid sequence that can pass through the cell membrane of the phospholipid bilayer per se and is not particularly limited, but may be composed of the amino acid sequence of SEQ ID NO: 16 .
  • the transmembrane sequence domain when introduced into the fusion protein, it is preferably located in the N terminal direction of the fusion protein, but is not limited thereto.
  • nucleus-cytoplasm signal domain is interpreted to mean a polydide sequence that serves to transport fusion proteins into or out of the nucleus.
  • the nuclear cell cytoplasmic signal domain may be a NLSCnucleus location sequence (NLSCnucleus location sequence) domain or NES (nucleus export sequence) domain. That is, NLS may be included in the fusion protein to transfer the fusion protein into the nucleus, and NES may be included in the fusion protein in order to keep the fusion protein in the cytoplasm.
  • NLS domains are proteins that are transported from the cytoplasm to the nucleus
  • NES domains are characterized by proteins that are transported from the nucleus to the cytoplasm, all of which refer to polypeptides having an amino acid sequence that can pass through the nuclear membrane.
  • the polypeptide which may be used as the NLS domain is not particularly limited.
  • the polypeptide may be KKKRK (SEQ ID NO: 17), PKKKRKV (SEQ ID NO: 18), KRPAATKKAGQAKKKK (SEQ ID NO: 19), and the like. .
  • the nuclear-cytoplasmic signal domain in the fusion protein plays an important role in increasing the solubility of the protein, in addition to the important task of moving the fusion protein into and out of the nucleus, where it is located close to the C-terminus of the fusion protein. It is more helpful for the increase.
  • the term “in vivo stabilization protein” refers to a protein that provides stability to the fusion protein stably in a living body in which the fusion protein substantially acts.
  • the protein is a part of the fusion protein, and should not induce immunogenicity in vivo, and in particular, any protein can be used as long as it can obtain stability in the blood of the subject.
  • the in vivo stabilizing protein may be at least one selected from the group consisting of AAT (alpha 1 antitrypsin), serum albumin, serum albumin binding peptide (SABP), immunoglobulin Fc and PEG (polyethyleneglycol).
  • the in vivo stabilizing protein is fused. When incorporated into the protein, it may also be implemented between the N-terminal, C-terminal or the p53 protein and pl8 protein of the fusion protein.
  • a stop codon may be further included.
  • the stop codon may be inserted repeatedly two or more times, for example, a TAA sequence may be inserted twice.
  • STOPx2 the case where the stop codon is inserted twice is referred to as STOPx2 for convenience.
  • the present invention provides an annexin A1 binding protein, p53 protein or p53 protein fragment having the amino acid sequence of SEQ ID NO: 1, and pl8 or pl6 protein It provides a pharmaceutical composition for the prevention or treatment of cancer comprising the fusion protein comprising as an active ingredient.
  • the fusion protein may further include one or more selected from the group consisting of an in vitro stabilizing protein, a membrane permeation sequence domain, a nuclear-cytoplasmic signal domain, and an in vivo stabilizing protein, and the details thereof are as described above. .
  • the fusion protein is a fusion protein comprising an annexin A1 binding protein, p53 protein, and ⁇ 18 or pl6 protein in the N-terminal to C-terminal order;
  • a fusion protein comprising an annexin A1 binding protein, a pl8 or pl6 protein, and a p53 protein in the order of the N-terminus to the C-terminus;
  • a fusion protein comprising a p53 protein, a pl8 or pl6 protein, and an annexin A1 binding protein in the order of N-terminus to C-terminus;
  • the pl8 or pl6 protein, p53 protein and annexin A1 binding protein may be selected from the group consisting of a fusion protein comprising in the order of the N- terminal to the C- terminal.
  • the fusion protein is an annexin A1 binding protein, p53 protein, and pl8 or pl6 protein in the fusion protein comprising N-terminal ⁇ terminal, N-terminal direction of the p53 protein Or at least one member selected from the group consisting of an ex vivo stabilizing protein, a membrane permeation sequence domain and a nuclear cytoplasmic signal domain, or a membrane permeation sequence domain, a nuclear cytoplasmic signal in the C-terminal direction of a pl8 or pl6 protein.
  • a fusion protein further comprising at least one selected from the group consisting of a domain and an in vivo stabilizing protein; ,
  • fusion proteins comprising annexin A1 binding protein, pl8 or pl6 protein, and p53 protein in the N-terminus to C-terminus
  • membrane permeation sequence Further comprising one or more selected from the group consisting of a domain and a nuclear cytoplasmic signal domain, or selected from the group consisting of a membrane permeable sequence domain, a nuclear-cytoplasmic signal domain and an in vivo stabilizing protein in the C-terminal direction of the P53 protein.
  • 1 kind A fusion protein further comprising an ideal phase
  • a fusion protein comprising p53 protein, pl8 or pl6 protein, and annexin A1 binding protein in the order of N-terminus to C-terminus
  • in vitro stabilizing protein membrane permeation in the N-terminal direction of annexin A1 binding protein
  • It further comprises one or more selected from the group consisting of a sequence domain and a nuclear-cytoplasmic signal domain, or a membrane permeable sequence domain, a nuclear ⁇ cytoplasmic signal domain and an in vivo stabilizing protein in the C-terminal direction of the annexin A1 binding protein.
  • a fusion protein further comprising one or more selected from the group consisting of; And
  • a fusion protein comprising pl8 or pl6 protein, p53 protein and annexin A1 binding protein in the order of N-terminus to C-terminus
  • in vitro stabilizing protein membrane permeation sequence in the N-terminal direction of annexin A1 binding protein
  • membrane permeation sequence in the N-terminal direction of annexin A1 binding protein
  • at least one member selected from the group consisting of a domain and a nuclear cell cytoplasmic signal domain, or a membrane permeable sequence domain, a nuclear cytoplasmic signal domain, and an in vivo stabilizing protein in the C-terminal direction of the annexin A1 binding protein It may be selected from the group consisting of a fusion protein that further comprises one or more selected from the group.
  • the present invention also provides a polynucleotide encoding the fusion protein, a recombinant vector comprising the polynucleotide, and a cell transformed with the recombinant vector.
  • the present invention provides a method for producing a fusion protein comprising the step of culturing the transformed cells.
  • polynucleotide refers to a polymer of deoxyribonucleotides or ribonucleotides present in single- or double-stranded form. Such polynucleotides encompass RNA genomic sequences, cDNAs and RNA sequences transcribed therefrom, and include analogs of natural polynucleotides unless specifically noted otherwise.
  • the polynucleotide encoding the protein complex of the present invention may be one comprising the nucleic acid sequence of SEQ ID NO: 21.
  • the polynucleotide includes not only the nucleotide sequence encoding the amino acid sequence of the fusion protein but also a complementary sequence to the sequence.
  • the complementary sequence is perfectly In addition to complementary sequences, it also includes substantially complementary sequences that can be hybridized with nucleotide sequences encoding, for example, the amino acid sequence of the fusion protein, under stringent conditions known in the art. Means.
  • the recombinant vector may be an expression vector, which can stably express the fusion protein in a host cell.
  • the expression vector may be a conventional one used to express foreign proteins in plants, animals or microorganisms in the art.
  • the recombinant vector can be constructed through various methods known in the art.
  • the recombinant vector can be constructed using prokaryotic or eukaryotic cells as hosts.
  • a strong promoter capable of promoting transcription e.g., pLA promoter, trp promoter, lac promoter, tac promoter, T7 promoter, etc.
  • replication origins that operate in eukaryotic cells included in the vector include fl replication origin, SV40 replication origin, pMBl replication origin, adeno replication origin, AAV replication origin, and BBV replication origin. It is not limited.
  • promoters derived from the genome of mammalian cells eg, metallothionine promoters
  • promoters derived from mammalian viruses eg, adenovirus late promoters, vaccinia virus 7.5K promoters, SV40 promoters, Cytomegalovirus promoter and tk promoter of HSV
  • the transformed cell may be any host cell known in the art as the host cell capable of continuously cloning or expressing the recombinant vector, and as a prokaryotic cell, for example, E. coli Bacillus genus strains such as JM109, E. coll BL21, E. coli RRl, E. coJi LE392, E. coli B, E. coli X 1776, E. co // W3110, Bacillus subtilis, Bacillus thuringiensis, And enterococci and strains such as Salmonella typhimurium, Serratia marsonsons and various Pseudomonas species.
  • E. coli Bacillus genus strains such as JM109, E. coll BL21, E. coli RRl, E. coJi LE392, E. coli B, E. coli X 1776, E. co // W3110, Bacillus subtilis, Bacillus thuringiensis, And enterococci and strains such as Salmon
  • Ho—SX Saccharomyce cerevisiae, stromal cells, plant cells and animal cells for example, CHO cell line (Chinese hamster ovary), W138, BHK, COS-7, 293, HepG2, 3T3, RIN And MDCK cell lines can be used.
  • the delivery of the polynucleotide or recombinant vector comprising the same into a host cell may employ a delivery method well known in the art.
  • a delivery method well known in the art.
  • the host cell is a prokaryotic cell
  • a CaCl 2 method or an electroporation method may be used.
  • the host cell is a eukaryotic cell
  • a micro-injection method, a calcium phosphate precipitation method, an electroporation method, a liposome -Mediated transfection and gene bombardment may be used, but is not limited thereto.
  • the method of selecting the transformed host cell can be easily carried out according to methods well known in the art using a phenotype expressed by a selection label.
  • the selection marker is a specific antibiotic resistance gene
  • the transformant can be easily selected by culturing the transformant in a medium containing the antibiotic.
  • Cultivation of the transformed cells can be carried out through various methods known in the art.
  • the cells were cultured by inoculating the transformed cells in YT liquid medium, and then inducing and culturing protein expression by the / acZ promoter by adding IPTG to the medium when the cell density reached a certain level. Proteins secreted in vitro or in media can be obtained.
  • Proteins secreted into cells or into the medium can be obtained in purified form according to various purification methods known in the art. In purified form, for example, by solubility fractionation with ammonium sulphate, size fractional filtration and purification by various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity). Protein can be obtained. For example, when the fusion protein is fused to GST, the desired protein can be easily obtained by using a resin column bound to glutathione or a Ni 2+ -NTA His-bound resin column when fused to 6x His.
  • p53 and pl8 included in the fusion protein Or the pl6 fusion significantly increases the stability of p53, temporarily expresses the p21 gene and stops cell proliferation, and expresses the Bax gene to induce cell death and inhibit CDK 4, 6 activity. It is effective as an active ingredient in the prevention and / or treatment of cancer.
  • annexin A1 binding protein another component included in the fusion protein, binds to annexin A1 specifically expressed in cancer cells, thereby enabling cancer cell targeting so that the fusion protein can selectively act on only cancer cells. Therefore, the fusion protein of the present invention can be provided as a pharmaceutical composition for the prevention and / or treatment of cancer.
  • a pharmaceutical composition for preventing and / or treating cancer comprising the fusion protein as an active ingredient.
  • the pharmaceutical composition may further comprise a pharmaceutically acceptable carrier, diluent and / or excipient in an amount normally used as necessary.
  • the pharmaceutically acceptable carrier is conventionally used in the preparation, lactose, dextrose, sucrose, sorbbi, manny, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline Cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, stearic acid magnesium and mineral oils, including but not limited to no.
  • the pharmaceutical composition may further include a lubricant, a humectant, a sweetener, a flavoring agent, an emulsifier, a suspension preservative, and the like, in addition to the above components.
  • a method of preventing and / or treating cancer comprising administering a therapeutically effective amount of the fusion protein to an individual in need thereof.
  • the method for preventing and / or treating cancer may further comprise identifying a subject in need of ' prophylaxis and / or treatment of cancer prior to the administering step.
  • use is provided for use in the prevention and / or treatment of cancer of the fusion protein, or for use in the manufacture of a medicament for the prevention and / or treatment of cancer of the fusion protein.
  • the fusion protein or a pharmaceutical composition comprising the same as an active ingredient is a pharmaceutically acceptable carrier according to a method which can be easily carried out by those skilled in the art. And / or by formulating with excipients, they may be prepared in unit dose form or may be prepared within a multi-dose container.
  • the formulation may be in the form of solutions, suspensions, syrups or emulsions in oils or aqueous media, or in the form of extracts, powders, powders, granules, tablets or accelerators, and may further comprise dispersants or stabilizers.
  • the composition may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional medical agents.
  • the fusion protein or a pharmaceutical composition for preventing or treating cancer containing the same as an active ingredient may be administered orally or parenterally.
  • parenteral administration it can be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, endothelial administration, topical administration, intranasal administration, pulmonary administration and rectal administration.
  • oral administration because proteins or peptides are digested, oral compositions should be formulated to coat the active agent or to protect it from degradation in the stomach.
  • the composition may be administered by any device that allows the composition to migrate to the target cell.
  • Suitable dosages of the fusion protein or a pharmaceutical composition for preventing or treating cancer comprising the same as an active ingredient include a formulation method, a mode of administration, a patient's age, weight, sex, morbidity, food, time of administration, route of administration, and excretion rate. And various factors such as reaction responsiveness. Preferred dosages of the compositions are in the range of 0.001 to 100 mg / kg on an adult basis.
  • pharmaceutically effective amount or “therapeutically effective amount” means an amount that can be effective in preventing or treating cancer.
  • the patient to be administered the pharmaceutical composition for preventing or treating the fusion protein or cancer containing the same as an active ingredient may be a rodent including a mammal, for example, a primate including a human monkey, and the like.
  • the cancer to be prevented or treated by the fusion protein or pharmaceutical composition may be solid or hematologic cancer, for example, squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, squamous cell carcinoma of the lung Peritoneal cancer, skin cancer, skin or intraocular myeloma, rectal cancer, anal muscle cancer, esophageal cancer, small intestine cancer, endocrine cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, chronic or Acute leukemia, lymphoma, gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, breast cancer, colon cancer, colon cancer, endometrial or uterine cancer, salivary gland cancer, kidney cancer, prostate cancer, vulva cancer, thyroid cancer, head and neck cancer It may be selected from the group struggled by the back, but is not limited thereto.
  • one of the hydrophilic polypeptides is ubiquitin wild type protein or ubiquitin mutant protein, membrane transfer sequence (MTS), pi 8, in vivo stabilizing protein (AAT: alpha 1 antitrypsin), p53 fragment, nucleus.
  • An expression vector of the protein complex was prepared to produce a protein complex for intracellular delivery linked in the order of the nucleus localization signal domain (NLS).
  • an expression vector for producing a protein complex excluding one or more components from the protein complex was prepared for a comparative experiment with the protein complex.
  • wild type ubiquitin was referred to as Ub
  • a wild type ubiquitin C-terminal RGG was prepared.
  • the mutant ubiquitin modified with RGA is called Ubml.
  • a total of two kinds of expression vectors were prepared by Genotech Co., Ltd., and a vector for protein overexpression was pET-21b (+) (EMD Biosciences).
  • each insert DNA fragment comprises a nucleotide sequence that can be cleaved with Ndel at the 5 'end, and a nucleotide sequence that can be cleaved with Xhol at the 3' end, Ndel-Xhol cleavage of the pET21b (+) vector Can be inserted into the sequence.
  • a schematic diagram showing possible primary structures of the protein complex according to one embodiment is shown in FIG. 1.
  • Example 2 Expression and Purification of Fusion Proteins
  • the supernatant was obtained using a centrifuge (10,000 g). The supernatant was applied to a Ni 2+ -NTA superflow column (Qiagen) equilibrated with the complete solution, and the washed supernatant (50 mM Tris-HCl, pH 8.0, 5% glycerol) corresponding to 5 times the column volume. Wash the 5 mM ⁇ -mercaptoethane with 0.2% Triton X-100 and 1 M NaCl, and then elute the complete solution (50 mM Tris-HCl, pH 8.0, 5% glycerol, 5 mM ⁇ -mercapto).
  • Example 3 Confirmation of Calcium-dependent Binding of the Fusion Protein to Annexin A1
  • the protein complex # 1 and annexin A1 prepared in Example 2 contained calcium-free buffer (Tris-HCl 50 mM, 10% glycerol pH 7.6) or calcium.
  • the cells were each dispensed in RPMI medium (Gibco BL) containing 10% FBS with 5> ⁇ 10 3 per well in a 96-well plate.
  • the proteins were 0, 0.25, 0.5, 1, 2, 4uM and then incubated for 72 hours at a temperature of 37 0 C, C0 2 5% in a CO 2 incubator.
  • the protein complex-free buffer 0.1 arginine, 0.2% Tween20, 0.2% L-Glutathione, lXPBSCpH 7.4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une protéine de fusion, dans laquelle une protéine de liaison à l'annexine A1, une protéine p53 et une protéine p18 ou p16 sont conjuguées, la préparation de la protéine de fusion, et une composition pharmaceutique pour la prévention ou le traitement du cancer, contenant la protéine de fusion.
PCT/KR2014/004644 2013-05-24 2014-05-23 Protéine de fusion comprenant une protéine de liaison à l'annexine a1, protéine p53 et protéine p18 ou p16, et composition pour la prévention ou le traitement du cancer, la comprenant WO2014189335A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2013-0059277 2013-05-24
KR20130059277A KR20140138507A (ko) 2013-05-24 2013-05-24 아넥신 Ａ1 결합단백질, ｐ53 단백질, 및 ｐ18 또는 ｐ16 단백질을 포함하는 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 조성물

Publications (1)

Publication Number Publication Date
WO2014189335A1 true WO2014189335A1 (fr) 2014-11-27

Family

ID=51933820

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2014/004644 WO2014189335A1 (fr) 2013-05-24 2014-05-23 Protéine de fusion comprenant une protéine de liaison à l'annexine a1, protéine p53 et protéine p18 ou p16, et composition pour la prévention ou le traitement du cancer, la comprenant

Country Status (2)

Country Link
KR (1) KR20140138507A (fr)
WO (1) WO2014189335A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10799579B2 (en) 2015-01-16 2020-10-13 The Johns Hopkins University Methods for enhancing antigen-specific immune responses

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004098526A2 (fr) 2003-05-05 2004-11-18 Johns Hopkins University Vaccin a adn anti-cancer faisant appel a des plasmides codant une sequence-signal, un antigene oncoproteine mutant, et une proteine de choc thermique

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080032476A (ko) * 2006-10-10 2008-04-15 학교법인 한림대학교 아넥신 융합 단백질

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080032476A (ko) * 2006-10-10 2008-04-15 학교법인 한림대학교 아넥신 융합 단백질

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIRD ET AL.: "An autologous dendritic cell canine mammary tumor hybrid- cell fusion vaccine", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 60, no. 1, 2011, pages 87 - 97, XP019877353, DOI: doi:10.1007/s00262-010-0921-2 *
KABIR ET AL.: "Novel frameshift mutation in the p16/INK4A tumor suppressor gene in canine breast cancer alters expression from the p16/INK4A/p14ARF locus", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 114, no. 1, January 2013 (2013-01-01), pages 56 - 66 *
SHAW ET AL.: "Effects of loss of p53 and p16 function on life span and survival of human urothelial cells", INTERNATIONAL JOURNAL OF CANCER, vol. 116, no. 4, 2005, pages 634 - 639 *
ZHU ET AL.: "PTEN induces G1 cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells", CANCER RESEARCH, vol. 61, no. 11, 2001, pages 4569 - 4575 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10799579B2 (en) 2015-01-16 2020-10-13 The Johns Hopkins University Methods for enhancing antigen-specific immune responses
US11766478B2 (en) 2015-01-16 2023-09-26 The Johns Hopkins University Methods for enhancing antigen-specific immune responses

Also Published As

Publication number Publication date
KR20140138507A (ko) 2014-12-04

Similar Documents

Publication Publication Date Title
KR102578891B1 (ko) 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
Liou et al. The NF‐kappa B p50 precursor, p105, contains an internal I kappa B‐like inhibitor that preferentially inhibits p50.
Ma et al. Regulation of Stat3 nuclear import by importin α5 and importin α7 via two different functional sequence elements
Criqui et al. Cell cycle‐dependent proteolysis and ectopic overexpression of cyclin B1 in tobacco BY2 cells
Gytz et al. Apoptotic properties of the type 1 interferon induced family of human mitochondrial membrane ISG12 proteins
DK2661496T3 (en) FUSION PROTEIN AS ANTICANCING AGENT
JPH11313686A (ja) サイクリン依存性キナ―ゼの阻害剤の結合パ―トナ―、並びにそれらの阻害剤検索および疾病の診断または治療のための使用
CN105999227B (zh) FOXM1蛋白氮端（1-234 aa）的表达及其用途
AU2024201112A1 (en) Composition comprising VGLL1 peptide for treatment of cancer
Fujihara et al. Inhibition of NF-κB by a cell permeable form of IκBα induces apoptosis in eosinophils
KR102092345B1 (ko) 류신 지퍼 변이체 및 이의 용도
Yoo et al. JAB1 regulates CPNE1-related differentiation via direct binding to CPNE1 in HiB5 hippocampal progenitor cells
WO2014189335A1 (fr) Protéine de fusion comprenant une protéine de liaison à l'annexine a1, protéine p53 et protéine p18 ou p16, et composition pour la prévention ou le traitement du cancer, la comprenant
Wilson et al. Binding of HTLV-1 tax oncoprotein to the precursor of interleukin-16, a T cell PDZ domain-containing protein
Lamberti et al. Analysis of interaction partners for eukaryotic translation elongation factor 1A M-domain by functional proteomics
WO2015069044A1 (fr) Protéine de fusion comprenant la protéine p53 et la protéine p15 liées l'une à l'autre, et composition contenant ladite protéine de fusion pour la prévention ou le traitement du cancer
WO2015009082A1 (fr) Protéine de fusion comprenant la protéine de liaison annexine a2, la protéine p53 et la protéine p18, et composition la contenant pour la prévention ou le traitement du cancer
Maruta et al. Interfering with Ras signaling using membrane-permeable peptides or drugs
WO2015069061A1 (fr) Protéine hybride comprenant la protéine p53 et p16 protéine liées l'une à l'autre, et composition contenant ladite protéine hybride utile pour prévenir ou traiter le cancer
CN101096383A (zh) 表皮生长因子与绿色荧光蛋白的融合蛋白
CN114073760B (zh) Rdr蛋白在肿瘤治疗中的应用
WO2022261851A1 (fr) Application de protéines jaz végétales et de polypeptides dérivés dans la prévention et le traitement de tumeurs humaines et animales
Patel et al. The RET finger protein interacts with the hinge region of SMC3
Boissel et al. Identification and characterization of the RLIP/RALBP1 interacting protein Xreps1 in Xenopus laevis early development
Wojtal et al. Peptides derived from plant virus VPg protein inhibit eIF4E oncogene

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14800420

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14800420

Country of ref document: EP

Kind code of ref document: A1